Longboard pharmaceuticals announces closing of public offering and full exercise of underwriters' option to purchase additional shares in public offering of common stock

San diego--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its voting common stock, including the exercise in full by the underwriters of their option to purchase an additional 750,000 shares, at a price to the public of $4.00 per share.
LBPH Ratings Summary
LBPH Quant Ranking